{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:25:21Z","timestamp":1793060721282,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00464-025-12086-5","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T17:46:44Z","timestamp":1759254404000},"page":"8580-8589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Analysis of the long-term impact of glucagon-like peptide-1 (GLP-1) receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"Iwanger-I-Ter T.","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace C.","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus H.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan E.","family":"Azagury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yewande R.","family":"Alimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0928-1799","authenticated-orcid":false,"given":"Nicholas J.","family":"Prindeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"12086_CR1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2021) Overweight & obesity statistics. https:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/overweight-obesity"},{"key":"12086_CR2","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2023) Health risks of overweight & obesity. https:\/\/www.niddk.nih.gov\/health-information\/weight-management\/adult-overweight-obesity\/health-risks"},{"key":"12086_CR3","unstructured":"Grand View Research (n.d.) U.S. medical weight loss clinics market size report, 2030. https:\/\/www.grandviewresearch.com\/industry-analysis\/us-medical-weight-loss-clinics-market-report. Accessed 24 Mar 2025"},{"key":"12086_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryd\u00e9n L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH-H, Temelkova-Kurktschiev T, REWIND Investigators (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"12086_CR5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, K\u00f8ber L, Petrie MC, McMurray JJV (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"12086_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.pcd.2019.05.006","volume":"14","author":"J Moreno-Fernandez","year":"2020","unstructured":"Moreno-Fernandez J, Garcia-Seco JA, Seco Segura AM, Garcia-Seco F, Rozas Moreno PJ, Aguirre Sanchez-Covisa M (2020) Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice? Prim Care Diabetes 14:68\u201374. https:\/\/doi.org\/10.1016\/j.pcd.2019.05.006","journal-title":"Prim Care Diabetes"},{"key":"12086_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"12086_CR8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.soard.2022.02.008","volume":"18","author":"T Wu","year":"2022","unstructured":"Wu T, Wong CKH, Tang EHM, Man KKC, Wong SKH, Au ICH, Tse ETY, Chan EWY, Grieve E, Wu O, Ng EKW, Wong ICK (2022) The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study. Surg Obes Relat Dis 18:762\u2013771. https:\/\/doi.org\/10.1016\/j.soard.2022.02.008","journal-title":"Surg Obes Relat Dis"},{"key":"12086_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12594","volume":"13","author":"A Alshehri","year":"2023","unstructured":"Alshehri A, AlFaris N, Al Qahtani AM, Shams M, Yahia M (2023) Clinical effectiveness of liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: a real-world experience. Clin Obes 13:e12594. https:\/\/doi.org\/10.1111\/cob.12594","journal-title":"Clin Obes"},{"key":"12086_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I, STEP 2 Study Group (2021) Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397:971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"key":"12086_CR11","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41366-021-00739-z","volume":"45","author":"JH Park","year":"2005","unstructured":"Park JH, Kim JY, Choi JH, Park HS, Shin H-Y, Lee JM, Kim J-W, Ko H-J, Chon S, Kim BK, Kim CS (2005) Lim S (2021) Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. Int J Obes 45:776\u2013786. https:\/\/doi.org\/10.1038\/s41366-021-00739-z","journal-title":"Int J Obes"},{"key":"12086_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2337\/dc19-1745","volume":"43","author":"WT Garvey","year":"2020","unstructured":"Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O (2020) Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care 43:1085\u20131093. https:\/\/doi.org\/10.2337\/dc19-1745","journal-title":"Diabetes Care"},{"key":"12086_CR13","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/dom.13266","volume":"20","author":"C Guja","year":"2018","unstructured":"Guja C, Fr\u00edas JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J (2018) Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. Diabetes Obes Metab 20:1602\u20131614. https:\/\/doi.org\/10.1111\/dom.13266","journal-title":"Diabetes Obes Metab"},{"key":"12086_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/cen.14901","volume":"99","author":"SA Tee","year":"2023","unstructured":"Tee SA, Tsatlidis V, Razvi S (2023) The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes. Clin Endocrinol (Oxf) 99:401\u2013408. https:\/\/doi.org\/10.1111\/cen.14901","journal-title":"Clin Endocrinol (Oxf)"},{"key":"12086_CR15","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/dom.13167","volume":"20","author":"DJ Siskind","year":"2018","unstructured":"Siskind DJ, Russell AW, Gamble C, Winckel K, Mayfield K, Hollingworth S, Hickman I, Siskind V, Kisely S (2018) Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab 20:1050\u20131055. https:\/\/doi.org\/10.1111\/dom.13167","journal-title":"Diabetes Obes Metab"},{"key":"12086_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.13107","volume":"20","author":"S Unni","year":"2018","unstructured":"Unni S, Wittbrodt E, Ma J, Schauerhamer M, Hurd J, Ruiz-Negr\u00f3n N, McAdam-Marx C (2018) Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab 20:468\u2013473. https:\/\/doi.org\/10.1111\/dom.13107","journal-title":"Diabetes Obes Metab"},{"key":"12086_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11096-015-0219-8","volume":"38","author":"SA de Boer","year":"2016","unstructured":"de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K (2016) The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour. Int J Clin Pharm 38:144\u2013151. https:\/\/doi.org\/10.1007\/s11096-015-0219-8","journal-title":"Int J Clin Pharm"},{"key":"12086_CR18","doi-asserted-by":"publisher","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, Andreasen AH, Jensen CB, DeFronzo RA, NN8022-1922 Study Group (2015) Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314:687\u2013699. https:\/\/doi.org\/10.1001\/jama.2015.9676","DOI":"10.1001\/jama.2015.9676"},{"key":"12086_CR19","first-page":"523","volume":"72","author":"EFS van Velsen","year":"2014","unstructured":"van Velsen EFS, Lamers J, Blok V, van Leendert RJM, Kiewiet-Kemper RM (2014) A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice. Neth J Med 72:523\u2013527","journal-title":"Neth J Med"},{"key":"12086_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/dme.12137","volume":"30","author":"GC Hall","year":"2013","unstructured":"Hall GC, McMahon AD, Dain M-P, Wang E, Home PD (2013) Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med 30:681\u2013686. https:\/\/doi.org\/10.1111\/dme.12137","journal-title":"Diabet Med"},{"key":"12086_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050117","volume":"7","author":"DJ Cuthbertson","year":"2012","unstructured":"Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 7:e50117. https:\/\/doi.org\/10.1371\/journal.pone.0050117","journal-title":"PLoS ONE"},{"key":"12086_CR22","first-page":"2677","volume":"125","author":"G-H Yuan","year":"2012","unstructured":"Yuan G-H, Song W-L, Huang Y-Y, Guo X-H, Gao Y (2012) Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. Chin Med J Engl 125:2677\u20132681","journal-title":"Chin Med J Engl"},{"key":"12086_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4158\/EP.13.5.444","volume":"13","author":"P Viswanathan","year":"2007","unstructured":"Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P (2007) Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 13:444\u2013450. https:\/\/doi.org\/10.4158\/EP.13.5.444","journal-title":"Endocr Pract"},{"key":"12086_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/14656566.2023.2178900","volume":"24","author":"LF Valladales-Restrepo","year":"2023","unstructured":"Valladales-Restrepo LF, S\u00e1nchez-Ram\u00edrez N, Usma-Valencia AF, Gaviria-Mendoza A, Machado-Duque ME, Machado-Alba JE (2023) Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity. Expert Opin Pharmacother 24:535\u2013543. https:\/\/doi.org\/10.1080\/14656566.2023.2178900","journal-title":"Expert Opin Pharmacother"},{"key":"12086_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023780","volume":"100","author":"JS Park","year":"2021","unstructured":"Park JS, Kwon J, Choi HJ, Lee C (2021) Clinical effectiveness of liraglutide on weight loss in South Koreans: first real-world retrospective data on Saxenda in Asia. Medicine (Baltimore) 100:e23780. https:\/\/doi.org\/10.1097\/MD.0000000000023780","journal-title":"Medicine (Baltimore)"},{"key":"12086_CR26","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/dom.13335","volume":"20","author":"JA Overbeek","year":"2018","unstructured":"Overbeek JA, Heintjes EM, Huisman EL, Tikkanen CK, van Diermen AW, Penning-van Beest FJA, Herings RMC (2018) Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: evidence of improved glycaemic and weight control in obese people with type 2 diabetes. Diabetes Obes Metab 20:2093\u20132102. https:\/\/doi.org\/10.1111\/dom.13335","journal-title":"Diabetes Obes Metab"},{"key":"12086_CR27","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/dom.13672","volume":"21","author":"M Suliman","year":"2019","unstructured":"Suliman M, Buckley A, Al Tikriti A, Tan T, le Roux CW, Lessan N, Barakat M (2019) Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab 21:1498\u20131501. https:\/\/doi.org\/10.1111\/dom.13672","journal-title":"Diabetes Obes Metab"},{"key":"12086_CR28","doi-asserted-by":"publisher","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT, STEP 8 Investigators (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial. JAMA 327:138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619","DOI":"10.1001\/jama.2021.23619"},{"key":"12086_CR29","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1111\/dom.15141","volume":"25","author":"K Stefanakis","year":"2023","unstructured":"Stefanakis K, Kokkinos A, Argyrakopoulou G, Konstantinidou SK, Simati S, Kouvari M, Kumar A, Kalra B, Kumar M, Bontozoglou N, Kyriakopoulou K, Mantzoros CS (2023) Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone\/bupropion and can predict future weight loss and metabolic improvements: a 6-month long interventional study. Diabetes Obes Metab 25:2561\u20132574. https:\/\/doi.org\/10.1111\/dom.15141","journal-title":"Diabetes Obes Metab"},{"key":"12086_CR30","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, J\u00f3dar E, Kandler K, Rigas G, Wadden TA, Wharton S, STEP 5 Study Group (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28:2083\u20132091. https:\/\/doi.org\/10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"key":"12086_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31982","volume":"5","author":"W Ghusn","year":"2022","unstructured":"Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A (2022) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open 5:e2231982. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31982","journal-title":"JAMA Netw Open"},{"key":"12086_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.742873","volume":"12","author":"M Rodgers","year":"2021","unstructured":"Rodgers M, Migdal AL, Rodr\u00edguez TG, Chen Z-Z, Nath AK, Gerszten RE, Kasid N, Toschi E, Tripaldi J, Heineman B, Phan M, Ngo L, Maratos-Flier E, Dushay J (2021) Weight loss outcomes among early high responders to exenatide treatment: a randomized, placebo controlled study in overweight and obese women. Front Endocrinol 12:742873. https:\/\/doi.org\/10.3389\/fendo.2021.742873","journal-title":"Front Endocrinol"},{"key":"12086_CR33","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietil\u00e4inen KH, Rubino D, Batterham RL (2021) Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398:2160\u20132172. https:\/\/doi.org\/10.1016\/S0140-6736(21)01751-7","journal-title":"Lancet"},{"key":"12086_CR34","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial. Lancet Lond Engl 397:1736\u20131748. https:\/\/doi.org\/10.1016\/S0140-6736(21)00845-X","journal-title":"Lancet Lond Engl"},{"key":"12086_CR35","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D, STEP 4 Investigators (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325:1414\u20131425. https:\/\/doi.org\/10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"12086_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O\u2019Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT, STEP 3 Investigators (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325:1403\u20131413. https:\/\/doi.org\/10.1001\/jama.2021.1831","journal-title":"JAMA"},{"key":"12086_CR37","doi-asserted-by":"publisher","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","DOI":"10.1056\/NEJMoa2032183"},{"key":"12086_CR38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH (2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet Lond Engl 392:637\u2013649. https:\/\/doi.org\/10.1016\/S0140-6736(18)31773-2","journal-title":"Lancet Lond Engl"},{"key":"12086_CR39","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E (2016) Effect of liraglutide 30 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes 40:1310\u20131319. https:\/\/doi.org\/10.1038\/ijo.2016.52","journal-title":"Int J Obes"},{"key":"12086_CR40","doi-asserted-by":"publisher","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH, SCALE Obesity and Prediabetes NN8022-1839 Study Group (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892","DOI":"10.1056\/NEJMoa1411892"},{"key":"12086_CR41","doi-asserted-by":"publisher","first-page":"8740","DOI":"10.26355\/eurrev_202309_33796","volume":"27","author":"S Cetiner","year":"2023","unstructured":"Cetiner S (2023) A single-center study on the biochemical effect and clinical effectiveness of liraglutide in Turkish patients. Eur Rev Med Pharmacol Sci 27:8740\u20138753. https:\/\/doi.org\/10.26355\/eurrev_202309_33796","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"12086_CR42","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1210\/clinem\/dgab408","volume":"106","author":"KE Elkind-Hirsch","year":"2021","unstructured":"Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D (2021) Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab 106:3019\u20133033. https:\/\/doi.org\/10.1210\/clinem\/dgab408","journal-title":"J Clin Endocrinol Metab"},{"key":"12086_CR43","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, M\u00f8ller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, N\u00fa\u00f1ez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC, STEP-HFpEF Trial Committees and Investigators (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069\u20131084. https:\/\/doi.org\/10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"12086_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/oby.23596","volume":"31","author":"S Santini","year":"2023","unstructured":"Santini S, Vionnet N, Pasquier J, Gonzalez-Rodriguez E, Fraga M, Pitteloud N, Favre L (2023) Marked weight loss on liraglutide 3.0 mg: real-life experience of a Swiss cohort with obesity. Obesity 31:74\u201382. https:\/\/doi.org\/10.1002\/oby.23596","journal-title":"Obesity"},{"key":"12086_CR45","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1159\/000518325","volume":"14","author":"CL Haase","year":"2021","unstructured":"Haase CL, Serratore Achenbach MG, Lucrezi G, Jeswani N, Maurer S, Egermann U (2021) Use of liraglutide 3.0 mg for weight management in a real-world setting in Switzerland. Obes Facts 14:568\u2013576. https:\/\/doi.org\/10.1159\/000518325","journal-title":"Obes Facts"},{"key":"12086_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107548","volume":"34","author":"KE Elkind-Hirsch","year":"2020","unstructured":"Elkind-Hirsch KE, Shaler D, Harris R (2020) Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight\/obese women with recent gestational diabetes: a double-blind, randomized, placebo-controlled study. J Diabetes Complications 34:107548. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107548","journal-title":"J Diabetes Complications"},{"key":"12086_CR47","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.2016.1252","volume":"315","author":"I Lingvay","year":"2016","unstructured":"Lingvay I, P\u00e9rez Manghi F, Garc\u00eda-Hern\u00e1ndez P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB, DUAL V Investigators (2016) Effect of insulin glargine up-titration vs insulin degludec\/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 315:898\u2013907. https:\/\/doi.org\/10.1001\/jama.2016.1252","journal-title":"JAMA"},{"key":"12086_CR48","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skj\u00f8th TV, Manning LS, Pi-Sunyer X, SCALE Obesity Prediabetes NN8022-1839 Study Group (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389:1399\u20131409. https:\/\/doi.org\/10.1016\/S0140-6736(17)30069-7","journal-title":"Lancet"},{"key":"12086_CR49","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jdiacomp.2016.01.013","volume":"30","author":"H Quan","year":"2016","unstructured":"Quan H, Zhang H, Wei W, Fang T (2016) Gender-related different effects of a combined therapy of exenatide and metformin on overweight or obesity patients with type 2 diabetes mellitus. J Diabetes Complic 30:686\u2013692. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.01.013","journal-title":"J Diabetes Complic"},{"issue":"5","key":"12086_CR50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ijo.2013.149","volume":"38","author":"MEJ Lean","year":"2014","unstructured":"Lean MEJ, Carraro R, Finer N, Hartvig H, Lindegaard ML, R\u00f6ssner S, Van Gaal L, Astrup A, NN8022-1807 Investigators (2014) Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes 38(5):689\u2013697. https:\/\/doi.org\/10.1038\/ijo.2013.149","journal-title":"Int J Obes"},{"key":"12086_CR51","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4158\/EP11169.OR","volume":"18","author":"A Varanasi","year":"2012","unstructured":"Varanasi A, Patel P, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P (2012) Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors. Endocr Pract 18:140\u2013145. https:\/\/doi.org\/10.4158\/EP11169.OR","journal-title":"Endocr Pract"},{"key":"12086_CR52","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1463-1326.2011.01393.x","volume":"13","author":"KY Thong","year":"2011","unstructured":"Thong KY, Jose B, Sukumar N, Cull ML, Mills AP, Sathyapalan T, Shafiq W, Rigby AS, Walton C, Ryder REJ, ABCD Nationwide Exenatide Audit Contributors (2011) Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. Diabetes Obes Metab 13:703\u2013710. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01393.x","journal-title":"Diabetes Obes Metab"},{"key":"12086_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clinthera.2007.01.015","volume":"29","author":"JB Buse","year":"2007","unstructured":"Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29:139\u2013153. https:\/\/doi.org\/10.1016\/j.clinthera.2007.01.015","journal-title":"Clin Ther"},{"key":"12086_CR54","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.dsx.2018.09.007","volume":"13","author":"A Hemmer","year":"2019","unstructured":"Hemmer A, Maiter D, Buysschaert M, Preumont V (2019) Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: a retrospective real-life study in 131 patients. Diabetes Metab Syndr 13:332\u2013336. https:\/\/doi.org\/10.1016\/j.dsx.2018.09.007","journal-title":"Diabetes Metab Syndr"},{"key":"12086_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"12086_CR56","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T, SUSTAIN-6 Investigators (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"12086_CR57","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsb\u00f8ll T, Warren ML, Bain SC, PIONEER 6 Investigators (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"},{"key":"12086_CR58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R, FLOW Trial Committees and Investigators (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391:109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"12086_CR59","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2337\/dc13-2761","volume":"37","author":"M Nauck","year":"2014","unstructured":"Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z (2014) Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 37:2149\u20132158. https:\/\/doi.org\/10.2337\/dc13-2761","journal-title":"Diabetes Care"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-025-12086-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-025-12086-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-025-12086-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T20:44:58Z","timestamp":1765917898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-025-12086-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["12086"],"URL":"https:\/\/doi.org\/10.1007\/s00464-025-12086-5","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors, including Mrs. Iwanger-T-Ter Jia, Mrs. Grace Bloomfield, Mr. Mike Chen, Mr. Marcus Cunningham, Dr. Dan Azagury, Dr. Yewande Alimi, and Dr. Nicholas Prindeze, have no financial disclosures, commercial associations, or other conditions posing a conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}